Completed PHASE2 INTERVENTIONAL 2-arm NCT01569451

Comparison of Rituximab Induction Therapy Followed by Glatiramer Acetate (GATEWAYII)

A Double Blinded, Randomized Study Comparing Rituximab Induction Therapy Followed by Glatiramer Acetate Therapy to Glatiramer Acetate Monotherapy in Patients With Relapsing Forms of Multiple Sclerosis

Sponsor: Rocky Mountain MS Research Group, LLC

Conditions Multiple Sclerosis

Interventions Glatiramer Acetate Placebo Rituximab

Updated 9 times since 2017 Last updated: Jun 6, 2018 Started: Feb 29, 2012 Primary completion: May 31, 2015 Completion: May 31, 2015

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Multiple Sclerosis, this trial is completed. The trial is conducted by Rocky Mountain MS Research Group, LLC and has accumulated 9 data snapshots since 2012. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

9 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2023 — Jul 2024 [monthly]

Completed PHASE2
Dec 2022 — Jan 2023 [monthly]

Completed PHASE2
Jan 2021 — Dec 2022 [monthly]

Completed PHASE2

▶ Show 4 earlier versions

Jul 2018 — Jan 2021 [monthly]

Completed PHASE2
Jun 2018 — Jul 2018 [monthly]

Completed PHASE2
Feb 2017 — Jun 2018 [monthly]

Completed PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Feb 2012

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Rocky Mountain MS Research Group, LLC
University of Colorado, Denver

Data source: University of Colorado, Denver

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Aurora, United States